Table 2. Adverse effects according to intensity and group of treatment.
| Adverse effect | Group of Treatment | Total n (%) | ||
| 20mg Sb5+/kg/day N (%) | 5 mg Sb5+/kg/day n (%) | |||
| Hyperlipasemia* (N=62) | Grade I | 08 (12.9) | 09 (14.5) | 17 (27.4) |
| Grade II | 08 (12.9) | 02 (3.2) | 10 (16.1) | |
| Grade III | 06 (9.7) | 01** (1.6) | 07 (11.3) | |
| Total | 22 (35.5) | 12 (19.3) | 34 (54.8) | |
| Hyperamylasemia (N=72) | Grade I | 09 (12.5) | 04 (5.6) | 13 (18.1) |
| Grade II | 01 (1.4) | 0 | 01 (1.4) | |
| Total | 10 (13.9) | 04 (5.5) | 14 (19.4) | |
| Hyperlipasemia + Hyperamylasemia*** (N=62) | 10 (13.9) | 03 (4.2) | 13 (18.1) | |
| Anorexia (N=72) | Grade I | 17 (23.6) | 07 (9.7) | 24 (33.3) |
| Vomiting (N=72) | Grade I | 05 (6.9) | 05 (6.9) | 10 (13.9) |
| Grade II | 01 (1.4) | 0 | 01 (1.4) | |
| Abdominal pain (N=72) | Grade I | 06 (8.3) | 02 (2.8) | 08 (11.1) |
| Grade II | 02 (2.8) | 03 (4.1) | 05 (6.9) | |
| Náusea (N=72) | Grade I | 08 (11.1) | 11 (15.2) | 19 (26.3) |
| Grade II | 01 (1.4) | 01 (1.4) | 02 (2.8) | |
N = Total number of evaluated patients; n = Number of patients with altered exam or symptom. % = percent of patients with altered exam or symptom. * Only 62 patients had serum lipase measured, 30 in 5 mg/kg/day group and 32 in 20 mg/kg/day group. ** Patient was included in the study with hyperlipasemia grade I. *** One patient with hyperamylasemia had not serum lipase measured; Sb5+ = pentavalent antimony